专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US10973783B2 Methods and compositions for the treatment of seizure-related disorders 有权
公开(公告)号：US10973783B2
公开(公告)日：2021-04-13
申请号：US15396161
申请日：2016-12-30
申请人： Adamas Pharmaceuticals, Inc.
发明人： Jack Nguyen , David Chernoff , Sangita Ghosh , Gregory T. Went , Timothy J. Fultz
IPC分类号： A61K31/165 , A61K9/16 , A61K9/50 , A61K31/4015 , A61K9/00 , A61K31/19 , A61K31/192 , A61P25/08
摘要： Compositions and methods are provided for administering a pharmaceutical composition to a human patient. Compositions are administered to a human patient orally, once daily, at a therapeutically effective dose. The pharmaceutical compositions comprise a drug selected from the group consisting of brivaracetam, divalproex, lacosamide, levetiracetam, oxcarbazepine, vigabatrin, and pharmaceutically acceptable salts of any of the foregoing, and at least one excipient. At least one of said at least one excipients modifies the release of said drug to provide an extended release form. The pharmaceutical composition have pharmacokinetic properties recited in the claims.

2. 发明申请

US20170189342A1 Methods and Compositions for the Treatment of Seizure-Related Disorders 审中-公开
公开(公告)号：US20170189342A1
公开(公告)日：2017-07-06
申请号：US15396161
申请日：2016-12-30
申请人： Adamas Pharmaceuticals, Inc.
发明人： Jack Nguyen , David Chernoff , Sangita Ghosh , Gregory T. Went , Timothy J. Fultz
IPC分类号： A61K9/50 , A61K31/165 , A61K31/4015 , A61K9/00
CPC分类号： A61K9/5078 , A61K9/0053 , A61K9/5026 , A61K9/5042 , A61K9/5047 , A61K31/165 , A61K31/19 , A61K31/192 , A61K31/395 , A61K31/4015 , A61K31/55
摘要： Compositions and methods are provided for administering a pharmaceutical composition to a human patient. Compositions are administered to a human patient orally, once daily, at a therapeutically effective dose. The pharmaceutical compositions comprise a drug selected from the group consisting of brivaracetam, divalproex, lacosamide, levetiracetam, oxcarbazepine, vigabatrin, and pharmaceutically acceptable salts of any of the foregoing, and at least one excipient. At least one of said at least one excipients modifies the release of said drug to provide an extended release form. The pharmaceutical composition have pharmacokinetic properties recited in the claims.

3. 发明申请

US20140343164A1 COMPOSITION AND METHOD FOR TREATING NEUROLOGICAL DISEASE 有权
公开(公告)号：US20140343164A1
公开(公告)日：2014-11-20
申请号：US14451282
申请日：2014-08-04
申请人： Adamas Pharmaceuticals, Inc.
发明人： Gregory T. Went , Timothy J. Fultz , Seth Porter , Laurence R. Meyerson , Timothy S. Burkoth
IPC分类号： A61K31/13 , A61K9/48 , A61K9/16 , A61K9/00
CPC分类号： A61K31/13 , A61K9/0004 , A61K9/0053 , A61K9/16 , A61K9/1617 , A61K9/1652 , A61K9/2009 , A61K9/2054 , A61K9/2846 , A61K9/4808 , A61K9/5021 , A61K9/5047 , A61K9/5078 , A61K31/197 , A61K31/198 , A61K45/06 , A61K2300/00
摘要： Disclosed are compositions comprising amantadine, or a pharmaceutically acceptable salt thereof, and one or more excipients, wherein at least one of the excipients modifies release of amantadine. Methods of administering the same are also provided.

4. 发明申请

US20140343154A1 COMPOSITION AND METHOD FOR TREATING NEUROLOGICAL DISEASE 有权
公开(公告)号：US20140343154A1
公开(公告)日：2014-11-20
申请号：US14451273
申请日：2014-08-04
申请人： Adamas Pharmaceuticals, Inc.
发明人： Gregory T. Went , Timothy J. Fultz , Seth Porter , Laurence R. Meyerson , Timothy S. Burkoth
IPC分类号： A61K31/13 , A61K9/16 , A61K9/48 , A61K31/198 , A61K9/00
CPC分类号： A61K31/13 , A61K9/0004 , A61K9/0053 , A61K9/16 , A61K9/1617 , A61K9/1652 , A61K9/2009 , A61K9/2054 , A61K9/2846 , A61K9/4808 , A61K9/5021 , A61K9/5047 , A61K9/5078 , A61K31/197 , A61K31/198 , A61K45/06 , A61K2300/00
摘要： Disclosed are compositions comprising amantadine, or a pharmaceutically acceptable salt thereof, and one or more excipients, wherein at least one of the excipients modifies release of amantadine. Methods of administering the same are also provided.

5. 发明申请

US20140343152A1 COMPOSITION AND METHOD FOR TREATING NEUROLOGICAL DISEASE 有权
公开(公告)号：US20140343152A1
公开(公告)日：2014-11-20
申请号：US14451226
申请日：2014-08-04
申请人： Adamas Pharmaceuticals, Inc.
发明人： Gregory T. Went , Timothy J. Fultz , Seth Porter , Laurence R. Meyerson , Timothy S. Burkoth
IPC分类号： A61K31/13 , A61K31/198
CPC分类号： A61K31/13 , A61K9/0004 , A61K9/0053 , A61K9/16 , A61K9/1617 , A61K9/1652 , A61K9/2009 , A61K9/2054 , A61K9/2846 , A61K9/4808 , A61K9/5021 , A61K9/5047 , A61K9/5078 , A61K31/197 , A61K31/198 , A61K45/06 , A61K2300/00
摘要： Disclosed are compositions comprising amantadine, or a pharmaceutically acceptable salt thereof, and one or more excipients, wherein at least one of the excipients modifies release of amantadine. Methods of administering the same are also provided.

6. 发明授权

US08598233B2 Method for administering an NMDA receptor antagonist to a subject 有权
标题翻译：给受试者施用NMDA受体拮抗剂的方法
公开(公告)号：US08598233B2
公开(公告)日：2013-12-03
申请号：US13751876
申请日：2013-01-28
申请人： Adamas Pharmaceuticals, Inc.
发明人： Gregory T. Went , Timothy J. Fultz , Laurence R. Meyerson
IPC分类号： A61K9/00 , A61K31/17 , A01N47/28
CPC分类号： A61K31/13 , A61K9/4891 , Y10S514/964
摘要： Compositions and methods for administering memantine to a subject are provided. In particular, a solid pharmaceutical composition in a unit dosage form for once daily oral administration is provided. The compositions comprises an extended release formulation of 22.5 mg to 33.75 mg memantine, or a pharmaceutically acceptable salt thereof, wherein administration of a dose of the composition to a human subject provides a mean plasma memantine concentration profile characterized by a change in memantine concentration as a function of time (dC/dT) that is less than 50% of the dC/dT provided by the same quantity of an immediate release form of memantine, determined in a time period between 0 hours to 6 hours after administration of memantine, and wherein dC/dT is measured in a single-dose human PK study. Methods of treating dementia, in particular Alzheimer's diseases, using the compositions are provided.
摘要翻译：提供了向受试者施用美金刚的组合物和方法。特别地，提供了一次每日口服给药的单位剂型的固体药物组合物。组合物包含22.5mg至33.75mg美金刚或其药学上可接受的盐的延长释放制剂，其中向人受试者施用该剂量的组合物提供了以美金刚浓度变化为特征的平均血浆美金刚浓度分布时间的函数（dC / dT）小于在美金刚给药后0小时至6小时之间的时间段内由相同量的美金刚立即释放形式提供的dC / dT的50％，其中在单次剂量人体PK研究中测量dC / dT。提供了使用该组合物治疗痴呆，特别是阿尔茨海默氏病的方法。

7. 发明申请

US20130165517A1 Composition and Method for Treating Neurological Disease 审中-公开
标题翻译：治疗神经病的组合物和方法
公开(公告)号：US20130165517A1
公开(公告)日：2013-06-27
申请号：US13756275
申请日：2013-01-31
申请人： ADAMAS PHARMACEUTICALS, INC.
发明人： Gregory T. Went , Timothy J. Fultz , Seth Porter , Laurence R. Meyerson , Timothy S. Burkoth
IPC分类号： A61K31/197 , A61K31/13
CPC分类号： A61K31/13 , A61K9/0004 , A61K9/0053 , A61K9/16 , A61K9/1617 , A61K9/1652 , A61K9/2009 , A61K9/2054 , A61K9/2846 , A61K9/4808 , A61K9/5021 , A61K9/5047 , A61K9/5078 , A61K31/197 , A61K31/198 , A61K45/06 , A61K2300/00
摘要： A method of treating a patient with Parkinson's disease is provided. The method comprises orally administering to the patient a first agent comprising levodopa and once-daily, orally administering to the patient a second agent comprising amantadine, or a pharmaceutically acceptable salt thereof. The amount of levodopa administered is reduced by 20% to 80% of the amount required in the absence of amantadine.
摘要翻译：提供了治疗帕金森病患者的方法。该方法包括向患者口服给予左旋多巴的第一药剂，每日一次，向患者口服给予包含金刚烷胺或其药学上可接受的盐的第二药剂。给予的左旋多巴的量减少了在没有金刚烷胺的情况下所需量的20％至80％。

8. 发明申请

US20130131110A1 Compositions for the Treatment of CNS-Related Conditions 有权
标题翻译： CNS相关条件治疗组合物
公开(公告)号：US20130131110A1
公开(公告)日：2013-05-23
申请号：US13725246
申请日：2012-12-21
申请人： Adamas Pharmaceuticals, Inc.
发明人： Gregory T. Went , Timothy J. Fultz , Laurence R. Meyerson
IPC分类号： A61K31/445 , A61K31/13
CPC分类号： A61K9/2054 , A61K9/0053 , A61K9/1635 , A61K9/1652 , A61K9/20 , A61K9/2009 , A61K9/2013 , A61K9/2059 , A61K9/2813 , A61K9/282 , A61K9/48 , A61K9/4808 , A61K9/7061 , A61K31/13 , A61K31/445 , A61K45/06 , Y02A50/401 , A61K2300/00
摘要： The invention provides compositions comprising extended release memantine in combination with immediate release donepezil to a subject. Memantine in an extended release form containing 22.5 to 30 mg memantine or a pharmaceutically acceptable salt thereof in combination with donepezil achieves particular pharmacokinetic criteria such as change in plasma concentration of memantine over time and ratio of maximum memantine plasma concentration to mean memantine plasma concentration.
摘要翻译：本发明提供了包含延长释放美金刚与即时释放多奈哌齐至受试者的组合物。包含22.5至30mg美金刚或其药学上可接受的盐与多奈哌齐组合的延长释放形式的美金刚获得特定的药代动力学标准，例如随时间推移美金刚血浆浓度的变化以及最大美金刚血浆浓度与平均美金刚血浆浓度之比。

9. 发明授权

US10987324B2 Methods and compositions for the treatment of seizure-related disorders 有权
公开(公告)号：US10987324B2
公开(公告)日：2021-04-27
申请号：US15863746
申请日：2018-01-05
申请人： Adamas Pharmaceuticals, Inc.
发明人： Jack Nguyen , David Chernoff , Sangita Ghosh , Gregory T. Went , Timothy J. Fultz
IPC分类号： A61K31/165 , A61K9/16 , A61K9/50 , A61K31/4015 , A61K9/00 , A61K31/19 , A61K31/192 , A61P25/08
摘要： Compositions and methods are provided for administering a pharmaceutical composition to a human patient. Compositions are administered to a human patient orally, once daily, at a therapeutically effective dose. The pharmaceutical compositions comprise a drug selected from the group consisting of brivaracetam, divalproex, lacosamide, levetiracetam, oxcarbazepine, vigabatrin, and pharmaceutically acceptable salts of any of the foregoing, and at least one excipient. At least one of said at least one excipients modifies the release of said drug to provide an extended release form. The pharmaceutical composition have pharmacokinetic properties recited in the claims.

10. 发明申请

US20160263058A1 COMPOSITION AND METHOD FOR TREATING NEUROLOGICAL DISEASE 审中-公开
公开(公告)号：US20160263058A1
公开(公告)日：2016-09-15
申请号：US14865830
申请日：2015-09-25
申请人： Adamas Pharmaceuticals, Inc.
发明人： Gregory T. Went , Timothy J. Fultz
IPC分类号： A61K31/13 , A61K9/00
CPC分类号： A61K31/13 , A61K9/0004 , A61K9/0053 , A61K9/16 , A61K9/1617 , A61K9/1652 , A61K9/2009 , A61K9/2054 , A61K9/2846 , A61K9/4808 , A61K9/5021 , A61K9/5047 , A61K9/5078 , A61K31/197 , A61K31/198 , A61K45/06 , A61K2300/00
摘要： Disclosed are compositions comprising amantadine, or a pharmaceutically acceptable salt thereof, and one or more excipients, wherein at least one of the excipients modifies release of amantadine. Methods of administering the same are also provided.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式